MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HOWLETT, D. R.
Right arrow Articles by NAHORSKI, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HOWLETT, D. R.
Right arrow Articles by NAHORSKI, S. R.

Molecular Pharmacology, Vol 15, 506-514, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics

Anomalous Properties of [3H]Spiperone Binding Sites in Various Areas of the Rat Limbic System

D. R. HOWLETT 1, HELEN MORRIS 1, and S. R. NAHORSKI 1

1 Department of Pharmacology and Therapeutics, Medical Sciences Building, University of Leicester, University Road, Leicester. LE1 7RH.

[3H]Spiperone, a neuroleptic/dopamine receptor ligand, binds with high affinity (Kd 0.15 nM) to a single specific site on rat corpus striatum membranes. The "specific" binding represents about 80% of the total binding and is displaced by dopamime, apomorphine, and stereospecifically by neuroleptics such as butaclamol and flupenthixol. However, in contrast to the striatum, only 30-40% of the binding of [3H]spiperone to limbic forebrain membranes is displaced stereospecifically by butaclamol or flupenthixol, whereas dopamine and certain spiperone analogues compete with high affinity for about 70% of the labeled sites. These additional sites are saturable, reversible, and of high affinity. Kinetic analysis of association and dissociation rates yields a Kd value (1.5 nM) in agreement with equilibrium saturation data for these sites. They also possess a precise distribution, with high amounts being found in the hippocampus, septum, and nucleus accumbens, but they are completely absent in areas such as the corpus striatum, olfactory tubercles and hypothalamus. Moreover, these [3H]spiperone binding sites show strict structure-affinity relationships in that only spirodecanone butyrophenone derivatives and dopamine are capable of displacing this binding with relatively high affinities.

The results emphasize the complex nature of neuroleptic/dopamine "receptor" binding sites in brain and the need for precise definition of such "specific" binding sites.

Note:
ACKNOWLEDGMENTS The authors would like to thank Dr. P. Laduron and Janssen Pharmaceutica for the samples of butyrophenone derivatives; the Wellcome Trust for financial support and Miss Jenny Bell for preparing the manuscript.

Submitted on September 7, 1978
Accepted on November 15, 1978




This article has been cited by other articles:


Home page
ScienceHome page
S. Treiser, C. Cascio, T. O'Donohue, N. Thoa, D. Jacobowitz, and K. Kellar
Lithium increases serotonin release and decreases serotonin receptors in the hippocampus
Science, September 25, 1981; 213(4515): 1529 - 1531.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics